Drug intelligence / Profile preview

TB-D004C

Development stage: Unknown
Lead developer: Shenzhen Turier Biotech
Administration: Subcutaneous

Overview

TB-D004C is an investigational drug candidate developed by Shenzhen Turier Biotech for the treatment of diabetic nephropathies. As of the latest pipeline information, the drug has received IND (Investigational New Drug) approval, marking its transition into clinical-stage development. While its specific molecular target and modality have not been publicly disclosed, Shenzhen Turier Biotech's broader portfolio focuses on organ fibrosis, anti-inflammatory conditions, and infectious diseases, suggesting that TB-D004C may target pathways involved in the progression of renal fibrosis or inflammation associated with diabetic kidney disease.

Targets

GLP1R (GLP-1R)GCGR (Glucagon receptor)

Beyond the preview

Go deeper on TB-D004C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TB-D004C.

Explore the full profile